Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Down 52.4% in December

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totaling 4,327 shares, a decrease of 52.4% from the November 30th total of 9,085 shares. Based on an average daily trading volume, of 79,708 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are sold short. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 79,708 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Investors Weigh In On Barinthus Biotherapeutics

A hedge fund recently raised its stake in Barinthus Biotherapeutics stock. Baird Financial Group Inc. grew its stake in shares of Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 108.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 192,461 shares of the company’s stock after acquiring an additional 100,000 shares during the quarter. Baird Financial Group Inc. owned about 0.48% of Barinthus Biotherapeutics worth $179,000 as of its most recent SEC filing. 25.20% of the stock is owned by institutional investors.

Barinthus Biotherapeutics Stock Up 0.4%

Shares of Barinthus Biotherapeutics stock opened at $0.70 on Monday. The company has a market cap of $28.75 million, a P/E ratio of -0.37 and a beta of -0.67. The firm’s 50 day moving average price is $0.90 and its 200-day moving average price is $1.11. Barinthus Biotherapeutics has a 52-week low of $0.64 and a 52-week high of $2.92.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its earnings results on Friday, November 7th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.09. As a group, equities research analysts forecast that Barinthus Biotherapeutics will post -1.38 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on the stock. HC Wainwright raised their target price on shares of Barinthus Biotherapeutics from $3.00 to $4.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Barinthus Biotherapeutics in a research note on Monday, December 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $4.00.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.